Literature DB >> 3861605

Enoxacin treatment of urinary tract infections.

M G Thomas, R B Ellis-Pegler.   

Abstract

We treated 20 patients with urinary tract infections with enoxacin, a new nalidixic acid analogue, in an open uncontrolled trial. Twelve of 13 patients with covert bacteriuria or cystitis and four of seven patients with pyelonephritis were cured. Two treatment failures occurred in patients with complicated infections. Nine patients reported mild side-effects.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3861605     DOI： 10.1093/jac/15.6.759

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  7 in total

1.  Enoxacin penetration into human prostatic tissue.

Authors:  M G Bergeron; R Roy; C Lessard; P Foucault
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 2.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

3.  Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  The effect of age on the pharmacokinetics of enoxacin.

Authors:  B R Dobbs; L R Gazeley; A J Campbell; I R Edwards
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 6.  Tissue penetration and clinical efficacy of enoxacin in urinary tract infections.

Authors:  S J Childs
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 7.  Clinical overview of enoxacin.

Authors:  S H Zinner
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.